Losing weight is hard, we make it a little bit easier with science. Mounjaro is the newest diabetes drug that also triggers dramatic weight loss in people who inject it. The U.S. Food and Drug Administration (FDA) approved Mounjaro a year ago for patients with diabetes.
It’s a completely new drug class. Instead of being a single-receptor agonist, which semaglutide (the drug in Ozempic and Wegovy) is, Mounjaro activates two receptors at the same time. That’s why it’s called a ‘dual-agonist’.
This double agonist approach seems to cause people who use Mounjaro injections to lose even more weight than those who use a single-agonist medication.
These receptors stimulate hormones that control blood sugar levels and reduce appetite, triggering weight loss. The receptors are known as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Wegovy and Ozempic activate the GLP-1 receptor, while Mounjaro activates two receptors: both GLP-1 and GIP.
We are dedicated to helping people achieve safe, effective, and permanent weight loss. It is always best to undergo a physician-supervised medical weight loss program to ensure that you are losing weight healthily and safely. To learn more about our weight loss plan, contact North Valley Cosmetic Surgery in Scottsdale, AZ to schedule a consultation appointment.
The safety and tolerability profile for tirzepatide is similar to other related drugs such as semaglutide and liraglutide. Mounjaro side effects may include:
Additional study is ongoing and looking closely for other unanticipated adverse effects. As of yet, there are no long term safety data on this drug.